Repligen (RGEN) Competitors $154.55 +5.03 (+3.36%) Closing price 04:00 PM EasternExtended Trading$157.50 +2.95 (+1.91%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN vs. TECH, A, DHR, MTD, TMO, BIIB, UTHR, INCY, NBIX, and IONSShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Mettler-Toledo International (MTD), Thermo Fisher Scientific (TMO), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector. Repligen vs. Its Competitors Bio-Techne Agilent Technologies Danaher Mettler-Toledo International Thermo Fisher Scientific Biogen United Therapeutics Incyte Neurocrine Biosciences Ionis Pharmaceuticals Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Do insiders & institutionals believe in TECH or RGEN? 99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 1.3% of Bio-Techne shares are held by insiders. Comparatively, 1.2% of Repligen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is TECH or RGEN more profitable? Bio-Techne has a net margin of 6.02% compared to Repligen's net margin of -2.05%. Bio-Techne's return on equity of 13.43% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Bio-Techne6.02% 13.43% 10.32% Repligen -2.05%4.61%3.24% Does the media favor TECH or RGEN? In the previous week, Bio-Techne had 4 more articles in the media than Repligen. MarketBeat recorded 21 mentions for Bio-Techne and 17 mentions for Repligen. Repligen's average media sentiment score of 0.71 beat Bio-Techne's score of 0.50 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 5 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Repligen 7 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, TECH or RGEN? Bio-Techne has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-Techne$1.22B7.86$73.40M$0.46133.91Repligen$634.44M13.70-$25.51M-$0.25-618.20 Which has more risk and volatility, TECH or RGEN? Bio-Techne has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Do analysts rate TECH or RGEN? Bio-Techne presently has a consensus price target of $70.58, indicating a potential upside of 14.58%. Repligen has a consensus price target of $169.62, indicating a potential upside of 9.75%. Given Bio-Techne's higher possible upside, analysts clearly believe Bio-Techne is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Techne 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.63Repligen 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.73 SummaryBio-Techne beats Repligen on 12 of the 16 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.41B$3.41B$6.09B$10.55BDividend YieldN/A2.29%5.73%4.78%P/E Ratio-618.1822.9385.0727.19Price / Sales13.70486.15604.99133.00Price / Cash48.1346.9737.8662.13Price / Book4.3910.5012.396.65Net Income-$25.51M-$52.47M$3.32B$276.79M7 Day Performance3.86%-1.00%-0.24%-1.51%1 Month Performance29.06%14.49%9.56%5.45%1 Year Performance11.85%13.92%71.67%36.24% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen4.444 of 5 stars$154.55+3.4%$169.62+9.7%+3.1%$8.41B$634.44M-618.181,778Trending NewsAnalyst RevisionGap UpTECHBio-Techne4.6868 of 5 stars$61.92-1.6%$70.42+13.7%-19.0%$9.80B$1.22B134.613,100Trending NewsAnalyst ForecastAnalyst RevisionAAgilent Technologies4.1807 of 5 stars$141.64flat$142.17+0.4%-3.8%$40.16B$6.51B33.2517,900Analyst ForecastAnalyst RevisionDHRDanaher4.9634 of 5 stars$211.65-1.6%$245.91+16.2%-24.3%$153.94B$23.88B45.0363,000Trending NewsUpcoming EarningsAnalyst RevisionMTDMettler-Toledo International4.2183 of 5 stars$1,345.35+2.4%$1,328.33-1.3%-10.3%$27.07B$3.87B34.0717,300Positive NewsTMOThermo Fisher Scientific4.8086 of 5 stars$544.44+0.2%$585.37+7.5%-12.2%$205.16B$42.88B31.49125,000Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionGap UpBIIBBiogen4.7389 of 5 stars$154.05-3.6%$180.04+16.9%-25.0%$23.44B$9.68B14.737,605Trending NewsAnalyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.5806 of 5 stars$453.28+0.0%$449.57-0.8%+20.2%$20.44B$2.88B17.691,305Insider TradeINCYIncyte4.4883 of 5 stars$87.23+0.4%$83.64-4.1%+33.0%$16.96B$4.24B19.832,617NBIXNeurocrine Biosciences4.7305 of 5 stars$139.43+1.8%$161.89+16.1%+17.4%$13.59B$2.36B41.251,800Positive NewsIONSIonis Pharmaceuticals3.3069 of 5 stars$69.02-0.2%$75.29+9.1%+91.3%$11.02B$705M-37.511,069Analyst ForecastInsider Trade Related Companies and Tools Related Companies Bio-Techne Alternatives Agilent Technologies Alternatives Danaher Alternatives Mettler-Toledo International Alternatives Thermo Fisher Scientific Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGEN) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredWhite House Letter Reveals “MAGA’s Master Plan”If you thought tariffs were big news, the next phase of MAGA’s economic plan could be far more transformative ...StocksToTrade | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
